Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tremelimumba

- PMLiVE

Amgen and AZ’s psoriasis antibody beats Stelara in study

Brodalumab cleared all skin lesions in 37% compared to Stelara’s 18.5%

Bristol-Myers Squibb (BMS) building

BMS’ PD-1 blocker Opdivo aces lung cancer trial

41% of treated patients alive after 12 months

- PMLiVE

Merck & Co’s cancer drug Keytruda gaining traction in US

Anti-PD-1 drug is used in around three quarters of eligible patients in US just weeks after FDA approval

- PMLiVE

NICE backs GSK’s Tafinlar for skin cancer

Joins Yervoy and Zelboraf as a recommended melanoma treatment

AstraZeneca AZ global R&D corporate HQ

AstraZeneca cements links with Cambridge University

Agrees a series of collaborations in areas such as Alzheimer's and multiple sclerosis

AZ launches breast cancer photo-sharing campaign

Social media campaign will see a selection of the pictures displayed in New York

Bristol Myers Squibb logo

First phase III data for BMS’ anti-PD1 nivolumab

Opdivo shows promise in melanoma study

- PMLiVE

AZ sets up joint lab with Cancer Research UK

Five-year collaboration will drive charity’s research programmes

- PMLiVE

NICE fast-tracks GSK’s skin cancer drug Tafinlar

But only on condition the company cuts its price

- PMLiVE

Merck brings first PD-1 inhibitor to US market

FDA approves Keytruda for advanced melanoma

- PMLiVE

Amgen submits melanoma and cholesterol drugs to EMA

Regulator will assess talimogene laherparepvec and evolocumab

- PMLiVE

NICE backs cancer drugs from Astellas and BMS

Recommendations for Xtandi in prostate cancer and earlier use of Yervoy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links